Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BRING-UP, as already known, is an observational study of outcome of the use of beta-blocker therapy for heart failure. This has been an extraordinary event in clinical medicine: a class of drugs, the beta-blockers, which clinical evidence transformed from being considered as contraindicated into being recommended. This exceptional situation, together with the growing awareness of the limited spread and applicability of evidence produced by trials into clinical practice led to undertaking observational studies to evaluate the feasibility, safety and practical results of the implementation of new therapies recommended for widespread use on the basis of results of controlled, randomized clinical trials. BRING-UP 1 will be followed by BRING-UP 2, the aim of this latter being to assess the effects of beta-blocker therapy on populations underrepresented in randomized trials, and SET-UP, on the use of GP IIb/IIIa platelet receptor inhibitors in unstable angina. BRING-UP has started a new line of research which does not substitute randomized trials, but complements and completes them. For this type of study to become common practice in clinical research, there must be greater interaction and acceptance by pharmaceutical companies and national and international regulatory bodies and a widespread conviction among doctors that this research has a paramount scientific, clinical and social value.
 ...
PMID:[Significance of the BRING-UP studies]. 1099 11

The BRING-UP 2 (ANMCO) is an observational study which evaluates the applicability, safety and efficacy profiles of beta-blockers in elderly patients and in those with severe heart failure. In this last category the recommendations for beta-blockers should be expanded, but in routine conditions of care the administration of these drugs still needs careful guide and observation.
 ...
PMID:[BRING-UP 2: presentation of the study]. 1099 12

This article continues a series of reports on recent research developments in the field of heart failure. Key presentations made at the European Society of Cardiology Heart Failure Update meeting, held in Wroclaw, Poland, in June 2004 are reported. The SHAPE study identified a need to educate general practitioners (GPs) in order to optimise treatment of heart failure in primary care. BRING-UP 2 VAS showed that cognitive impairment is very common in elderly heart failure patients and that these patients require specialist care. Carvedilol was shown to be well tolerated and effective in elderly heart failure patients in the observational COLA II study. In the FOSIDIAL study of patients with end-stage renal disease, fosinopril showed no benefit over placebo in reducing the incidence of cardiovascular events in these high-risk patients. The BETACAR study showed that carvedilol and metoprolol produced a similar effect on left ventricular ejection fraction (+13.1% and +12.0%, respectively). Revised mortality data for the CASINO study and a meta-analysis of the effects of cardiac resynchronisation therapy on mortality in the light of the recently published COMPANION study are reported.
 ...
PMID:Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. 1530 18